Biosimilar Medicines Need Strong Regulation, IP Crucial For Innovation, Pharma Says

Biosimilar medicines might prove to be a new reservoir for innovation for the pharmaceutical industry. However, the complexity of their manufacture needs a stringent regulatory framework, according to the industry.

Available only for IP-Watch Subscribers. Please login or subscribe to read the full story.

Catherine Saez may be reached at info@ip-watch.ch.

Attribution-Noncommercial-No Derivative Works 3.0 Unported

Leave a Reply